Experts find flaws in proposed Indian "Bayh-Dole" legislation
This article was originally published in Scrip
An Indian bill, which encourages the commercialisation of intellectual property (IP) from government-financed R&D for the larger public good, is being widely debated, with some experts claiming that it is flawed and could stymie potential gains from the open source drug discovery model.
You may also be interested in...
Top-level personnel movement continues at pharma firms in India, with Cipla now appointing an ex-Amneal executive as its Chief Scientific Officer, while Abbott has effected a rejig at the helm.
New rules in India specify that a marketer of a drug will share the onus for quality and compliance along with the manufacturer. Enhanced punishment for misleading advertisements for a range of illnesses is also proposed, while calls for a statute to regulate pharma's marketing practices grow louder.
Pfizer Upjohn’s Global President of R&D and Medical, Amrit Ray, discusses in a wide-ranging interview the need for tailored interventions to address the growing burden of non-communicable diseases and efforts around harnessing real world data. He also underscores the importance of investing in primary care and a primary health workforce against the backdrop of outbreaks such as coronavirus.